Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Microbot Medical Inc. - Common Stock (NQ:MBOT)

1.989 +0.009 (+0.47%)
Streaming Delayed Price Updated: 11:49 AM EDT, Jun 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Microbot Medical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System
A leading academic center becomes the first user in the Southeast, Mid-Atlantic region 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference
The presentation will be webcast live on April 15 at 10:15 a.m. ET. Continued Engagement with Healthcare Institutions Reflects Rising Momentum 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting
Successful Execution of the Limited Market Release (LMR) Includes Adoption by Globally Recognized Healthcare Systems in the U.S. Market and Demonstrates Broad Market Scalability in Key Endovascular... 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® to Participate at the 38th Annual Roth Conference
Live Webcast of Fireside Q&A Discussion on Monday, March 23, 2026 at 4:00 pm PT as it Nears its Full Market Release of the LIBERTY® in April 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time
Live Webcast on Thursday, March 19 at 8:40 am ET to Highlight the Expanding Clinical Experience with the LIBERTY® Endovascular Robotic System During the Limited Market Release 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation
LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare Providers 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
MBOT Stock Falls As Investors Ponder Impact Of Geopolitical Tensions On Israel-Founded Company ↗
Microbot said on Tuesday that it is not experiencing any disruption in either the U.S. or Israel with all personnel continuing to operate as usual. 
Via Stocktwits
News headline image
Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event
From Microbot Medical Inc.
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System
Early Post-Clearance Momentum Signals Accelerated Hospital Adoption of Advanced Robotics 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical®’s LIBERTY® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation Conference
Global Robotic Leaders Convene to Discuss & Highlight Surgical Advancements of the Next Decade with a Special Focus on the Endovascular Space 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption
Participating at the Society of Interventional Oncology Conference Will Allow the Company to Share Practical Insights and Personal Experiences 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System
Adoption of LIBERTY is Consistent with Emory’s Commitment to the Growing and Evolving Field of Interventional Radiology 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
$25.2 million in first closing, $1.2 million in second closing and $2.8 million in third and final closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon... 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Miocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System
Livestream Interview Can be Viewed on September 24th at 10:45am ET at Benzinga All Access Live 
From Microbot Medical Inc.
Via GlobeNewswire
News headline image
Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term... 
From Microbot Medical Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.